



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Plaque Psoriasis

Based on review of available data, the Company may consider secukinumab (Cosentyx™)‡ for the treatment of pediatric and adult patients with plaque psoriasis to be **eligible for coverage**.**

Patient Selection Criteria

Coverage eligibility for secukinumab (Cosentyx) will be considered when all of the following criteria are met:

- Patient has a diagnosis of moderate to severe plaque psoriasis; AND
- Patient is 6 years of age or older; AND
- Patient has a negative TB test (e.g. purified protein derivative [PPD], blood test) prior to treatment; AND
- Patient is a candidate for phototherapy or systemic therapy; AND
- Cosentyx is NOT used in combination with other biologic disease-modifying anti-rheumatic drugs (DMARDs), such as Humira®‡ or Enbrel®‡ OR other drugs such as Otezla®‡ or Xeljanz/XR®‡; AND
- Patient has greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function (such as palms, soles of feet, head/neck or genitalia); AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- Patient has failed to respond to an adequate trial of one of the following treatment modalities:
 - Ultraviolet B; OR

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

- Psoralen positive Ultraviolet A; OR
- Systemic therapy (i.e. methotrexate (MTX), cyclosporine, acitretin).
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

Psoriatic Arthritis

Based on review of available data, the Company may consider secukinumab (Cosentyx) for the treatment of adult patients with active psoriatic arthritis to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for secukinumab (Cosentyx) will be considered when all of the following criteria are met:

- Patient has a diagnosis of active psoriatic arthritis; AND
- Patient is 18 years of age or older; AND
- Patient has a negative TB test (e.g. purified protein derivative [PPD], blood test) prior to treatment; AND
- Cosentyx is NOT used in combination with other biologic disease-modifying anti-rheumatic drugs (DMARDs), such as Humira or Enbrel OR other drugs such as Otezla or Xeljanz/XR; AND
- Patient has failed treatment with one or more disease-modifying anti-rheumatic drugs (DMARDS).

*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

Ankylosing Spondylitis

Based on review of available data, the Company may consider secukinumab (Cosentyx) for the treatment of adult patients with active ankylosing spondylitis to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for secukinumab (Cosentyx) will be considered when all of the following criteria are met:

- Patient has a diagnosis of active ankylosing spondylitis; AND
- Patient is 18 years of age or older; AND

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

- Patient has a negative TB test (e.g. purified protein derivative [PPD], blood test) prior to treatment; AND
- Cosentyx is NOT used in combination with other biologic disease-modifying anti-rheumatic drugs (DMARDs), such as Humira or Enbrel OR other drugs such as Otezla or Xeljanz/XR; AND
- Patient has failed treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or has documented contraindications to non-steroidal anti-inflammatory drugs (NSAIDs) usage.
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*

Non-Radiographic Axial Spondyloarthritis

Based on review of available data, the Company may consider the use of secukinumab (Cosentyx) for the treatment of adult patients with non-radiographic axial spondyloarthritis to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for secukinumab (Cosentyx) will be considered when all of the following criteria are met:

- Patient has active non-radiographic axial spondyloarthritis as confirmed by the presence of sacroiliitis on magnetic resonance imaging (MRI); AND
- Patient has failed at least TWO months of current continuous therapy with at least TWO different oral NSAIDs (at prescription strength dosages) unless there is clinical evidence or patient history that suggests these products will be ineffective or cause an adverse reaction to the patient; AND
*(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).*
- Patient is 18 years of age or older; AND
- Cosentyx is NOT used in combination with other biologic DMARDs, such as Humira or Enbrel OR other drugs such as Otezla or Xeljanz/XR; AND
- Patient has a negative TB test (e.g., PPD, blood test) prior to treatment.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of secukinumab (Cosentyx) when any of the following criteria for their respective disease listed below (and denoted in the patient selection criteria above) are not met to be **not medically necessary****:

- For psoriatic arthritis:
 - Patient has failed treatment with one or more disease-modifying anti-rheumatic drugs (DMARDs)
- For ankylosing spondylitis:
 - Patient has failed treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or has documented contraindications to non-steroidal anti-inflammatory drugs (NSAIDs) usage
- For plaque psoriasis:
 - Patient has greater than 10% of body surface area (BSA) OR less than or equal to 10% BSA with plaque psoriasis involving sensitive areas or areas that would significantly impact daily function (such as palms, soles of feet, head/neck or genitalia)
 - Patient has failed to respond to an adequate trial of one of the following treatment modalities:
 - Ultraviolet B; OR
 - Psoralen positive Ultraviolet A; OR
 - Systemic therapy (i.e. methotrexate, cyclosporine, acitretin)
- For active non-radiographic axial spondyloarthritis:
 - Patient has failed at least TWO months of current continuous therapy with at least TWO different oral NSAIDs (at prescription strength dosages).

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of secukinumab (Cosentyx) when patient selection criteria are not met to be **investigational*** (with the exception of those denoted above as **not medically necessary****).

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

Based on review of available data, the Company considers the use of secukinumab (Cosentyx) for indications other than those listed above to be **investigational**.*

Background/Overview

Cosentyx is a human interleukin (IL)-17A antagonist indicated in patients 6 years and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, adults with active psoriatic arthritis, adults with active ankylosing spondylitis, and adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Cosentyx inhibits the release of pro-inflammatory cytokines and chemokines. Cosentyx is available in 150 mg dosages supplied as vials, pens, and prefilled syringes for subcutaneous injection. For pediatric patients, there is a 75 mg prefilled syringe available. The recommended dose of Cosentyx for plaque psoriasis in adults is 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. For some patients, a dose of 150 mg may be acceptable. In pediatric plaque psoriasis patients weighing ≥ 50 kg, the dose is 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks thereafter. For pediatric plaque psoriasis patients weighing less than 50 kg, the dose is 75 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, the dosing information for plaque psoriasis should be followed. If the patient has psoriatic arthritis or ankylosing spondylitis alone, or if the patient has non-radiographic axial spondyloarthritis, Cosentyx can be given with or without a loading dose. If a loading dose is given, it is a 150 mg loading dose at weeks 0, 1, 2, 3, and 4, and then 150 mg every 4 weeks thereafter. Without a loading dose, 150 mg every 4 weeks is recommended. For psoriatic arthritis and ankylosing spondylitis, a dosage of 300 mg every 4 weeks can be considered.

Plaque Psoriasis

Psoriasis is a common skin condition that is caused by an increase in production of skin cells. It is characterized by frequent episodes of redness, itching and thick, dry silvery scales on the skin. It is most commonly seen on the trunk, elbows, knees, scalp, skin folds and fingernails. This condition can appear suddenly or gradually and may affect people of any age; it most commonly begins between the ages of 15 and 35. Psoriasis is not contagious. It is an inherited disorder related to an inflammatory response in which the immune system produces too much TNF-alpha. It may be severe in immunosuppressed people or those who have other autoimmune disorders such as rheumatoid

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

arthritis. Treatment is focused on control of the symptoms and prevention of secondary infections. Lesions that cover all or most of the body may be acutely painful and require hospitalization. The body loses vast quantities of fluid and becomes susceptible to severe secondary infections that can involve internal organs and even progress to septic shock. Typical treatments for severe cases of plaque psoriasis include ultraviolet therapy or systemic therapies such as methotrexate or cyclosporine. Newer biologic therapies are also approved for the treatment of plaque psoriasis.

Psoriatic Arthritis

Psoriatic arthritis is an arthritis that is often associated with psoriasis of the skin. Typically first line treatments such as DMARDs (disease modifying anti-rheumatic drugs) are used to treat this condition. An example of a DMARD would include methotrexate.

Ankylosing Spondylitis

Ankylosing spondylitis is a chronic inflammatory disease that affects the joints between the vertebrae of the spine, and the joints between the spine and the pelvis. It eventually causes the affected vertebrae to fuse or grow together. Nonsteroidal anti-inflammatory drugs such as ibuprofen or naproxen are used to reduce inflammation and pain associated with the condition. Corticosteroid therapy or medications to suppress the immune system may be prescribed to control various symptoms.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Disease-modifying anti-rheumatic drugs are typically used for the treatment of inflammatory conditions. These drugs slow the disease process by modifying the immune system.

- methotrexate
- cyclosporine
- sulfasalazine
- mercaptopurine
- gold compounds

Non-Radiographic Axial Spondyloarthritis.

Axial spondyloarthritis is an inflammatory arthritis of the spine. It often presents as chronic back pain, typically before the age of 45 and is often associated with one or more articular features (e.g., synovitis, enthesitis, and dactylitis) and/or non-articular features (e.g., uveitis, psoriasis, and

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

inflammatory bowel diseases). Patients with this condition are classified as having one of two types of axial spondyloarthritis: either radiographic or non-radiographic. As supported by the name, the non-radiographic variety isn't evident on plain radiography and instead the diagnosis is supported by evidence of active inflammation of the sacroiliac joints via magnetic resonance imaging (MRI). Traditional pharmacologic therapy for the treatment of non-radiographic axial spondyloarthritis includes oral NSAIDs. Approximately 70-80% of patients with this condition report substantial relief with NSAID therapy. The effect of an NSAID is typically seen within two to four weeks and multiple NSAIDs need to be tried as patient response to a particular NSAID isn't predictable. Currently, Cimzia®† is the only TNF inhibitor product that is approved for non-radiographic axial spondyloarthritis. Most recently, Taltz®‡ and Cosentyx, both interleukin blockers, have gained approval for this indication. If a response to two NSAIDs has not proven beneficial, a tumor necrosis factor (TNF) alpha inhibitor, such as Cimzia, or an interleukin blocker, such as Taltz or Cosentyx, would be the next treatment option.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Cosentyx was approved by the FDA in January of 2015 for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. In January of 2016, Cosentyx gained additional indications for active psoriatic arthritis and active ankylosing spondylitis. In June of 2020, Cosentyx was granted FDA approved for adults with active non-radiographic axial spondyloarthritis. In May of 2021, the plaque psoriasis indication was expanded from 18 years of age and older to 6 years of age and older.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

Adult Plaque Psoriasis Studies

The safety and efficacy of Cosentyx was assessed in four pivotal studies in adults with plaque psoriasis. Study 1 randomized subjects to Cosentyx 300 mg, Cosentyx 150 mg, or placebo. Treatment was provided at weeks 0, 1, 2, 3, and 4 followed by dosing every 4 weeks. Subjects in the placebo group that were non-responders at week 12 were then crossed over to receive either dose of Cosentyx. All subjects were then followed for up to 52 weeks from the first administration of treatment. The proportion of subjects achieving a reduction in the Psoriasis Area and Severity Index (PASI) score of at least 75% (PASI 75) from baseline to week 12 and treatment success on the investigator's global assessment (IGA) were the primary endpoints. The PASI 75 response in the Cosentyx 300 mg, 150 mg, and placebo groups was 82%, 71%, and 4%, respectively. The percentage of patients achieving an IGA of clear or almost clear for the Cosentyx 300 mg, 150 mg, and placebo groups was 65%, 51%, and 2%, respectively. In patients treated with Cosentyx 300 mg and 150 mg, 81% and 72%, respectively, maintained PASI 75 response through week 52. Subjects that were clear or almost clear on the IGA also maintained their responses in 74% of subjects treated with Cosentyx 300 mg and in 59% of subjects treated with Cosentyx 150 mg.

Study 2 had a similar setup; however it also included a biologic active control (Enbrel). The PASI 75 response in the Cosentyx 300 mg, 150 mg, and placebo groups was 76%, 67%, and 5%, respectively. The percentage of patients achieving an IGA of clear or almost clear for the Cosentyx 300 mg, 150 mg, and placebo groups was 62%, 51%, and 3%, respectively. Similar results to study 1 were seen with maintaining responses in both PASI 75 and IGA in study 2. In regard to the biologic active control, Cosentyx 300 mg and 150 mg were superior to Enbrel at week 12 based on the PASI 75 response (77%, 67%, and 44%, respectively) as well as for the IGA measurement (63%, 51%, and 27%, respectively; $p=0.025$ for all comparisons). Both doses of Cosentyx were superior to Enbrel for maintaining PASI 75 and IGA response through week 52. Studies 3 and 4 were consistent with previous studies in which both doses of Cosentyx were superior to placebo in achieving PASI responses and IGA response for induction. Cosentyx trials also included measurements of PASI 90 as secondary outcomes.

Pediatric Plaque Psoriasis Studies

A 52-week, multicenter randomized, double-blind, placebo and active-controlled trial enrolled 162 pediatric subjects 6 years of age and older, with severe plaque psoriasis who were candidates for systemic therapy. Subjects were randomized to receive placebo, Cosentyx, or a biologic active control. In the Cosentyx groups, subjects with body weight < 25 kg received 75 mg, subjects with

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

body weight 25 to < 50 kg received either 75 mg or 150 mg (2 times the recommended dose), and subjects with body weight \geq 50 kg received either 150 mg or 300 mg (2 times the recommended dose). Subjects in the Cosentyx and placebo groups received treatment at weeks 0, 1, 2, 3, and 4 followed by dosing every 4 weeks. At week 12, subjects randomized to placebo who were non-responders were switched to Cosentyx (dose based on body weight) and received Cosentyx at weeks 12, 13, 14, and 15, followed by the same dose every 4 weeks starting at week 16.

The co-primary endpoints were the proportion of subjects who achieved a PASI 75 at week 12 and the proportion of subjects who achieved an IGA modified 2011 score of 'clear' or 'almost clear' (0 or 1) with at least a 2 point improvement from baseline to week 12. In those with body weight <50 kg on Cosentyx 75 mg, 55% of subjects achieved PASI 75 vs. 10% in the placebo group. In those with body weight \geq 50 kg on Cosentyx 150 mg, 86% of the subjects achieved PASI 75 vs 19% in the placebo group. In those with body weight <50 kg on Cosentyx 75 mg, 32% of subjects achieved IGA of clear or almost clear vs. 5% in the placebo group. In those with body weight \geq 50 kg on Cosentyx 150 mg, 81% of the subjects achieved IGA of clear or almost clear vs 5% in the placebo group.

Psoriatic Arthritis Studies

The safety and efficacy of Cosentyx were assessed in 1,003 patients in 2 randomized, double-blind, placebo-controlled trials in adult patients, age 18 years and older with active psoriatic arthritis. Study 1 for psoriatic arthritis evaluated 397 patients who were treated with Cosentyx 75 mg, 150 mg, or 300 mg at weeks 0, 1, 2, 3, and 4, followed by the same dose every 4 weeks. Patients receiving placebo were re-randomized to receive Cosentyx (either 150 mg or 300 mg every 4 weeks) at week 16 or week 24 based on responder status. The primary endpoint was the percentage of patients achieving a 20% improvement in the American College of Radiology score (ACR20) at week 24. In this study, patients treated with 150 mg or 300 mg of Cosentyx demonstrated a greater clinical response including ACR20, ACR50, and ACR70 compared to placebo at week 24. The percentage of patients achieving ACR20 at week 24 was 51% in the Cosentyx 150 mg group, 54% in the Cosentyx 300 mg group, and 15% in the placebo group. Results of the second study were not included in the package insert due to an intravenous loading dose being used (which is not approved in the United States).

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

Ankylosing Spondylitis Studies

The safety and efficacy of Cosentyx were assessed in 590 patients in two randomized, double-blind, placebo-controlled studies in adult patients 18 years of age and older with active ankylosing spondylitis. The first study for ankylosing spondylitis evaluated 219 patients who were treated with Cosentyx 75 mg or 150 mg at weeks 0, 1, 2, 3, and 4, followed by the same dose every 4 weeks. At week 16, patients receiving placebo were re-randomized to either Cosentyx 75 mg or 150 mg every 4 weeks. The primary endpoint was the percentage of patients achieving a 20 percent improvement in the Ankylosing Spondylitis Disease Activity Score (ASAS20) response at week 16. In this study, patients treated with 150 mg of Cosentyx demonstrated greater improvements in ASAS20 and ASAS40 responses compared to placebo at week 16. At week 16, 61% of patients taking Cosentyx 150 mg achieved ASAS20 vs. 28% taking placebo. Results of the second study were not included in the package insert due to an intravenous loading dose being used (which is not approved in the United States).

Non-Radiographic Axial Spondyloarthritis

The safety and efficacy of Cosentyx were assessed in 555 patients in one randomized, double-blind, placebo-controlled study in adult patients 18 years of age and older with active non-radiographic axial spondyloarthritis. Patients were treated with Cosentyx 150 mg with a loading dose (weeks 0, 1, 2, 3, and 4) or without a loading dose (weeks 0 and 4) followed by the same dose every 4 weeks or placebo. In the double-blind period, patients (n=555) received either placebo or Cosentyx for 52 weeks. Starting week 16, dose adjustment or addition of concomitant NSAIDs and DMARDs was permitted. Starting at week 20, patients were allowed to switch to open-label Cosentyx 150 mg monthly or other biologic at the discretion of the investigator and patient. The primary endpoint was at least a 40% improvement in Assessment of Spondyloarthritis International Society (ASAS40) at week 52. At week 52, the Cosentyx without a loading dose group had 38% of subjects achieving the primary endpoint versus 34% in the Cosentyx with a loading dose group versus 19% of subjects in the placebo group.

References

1. Cosentyx [package insert]. Novartis Pharmaceuticals. East Hanover, New Jersey. Updated May 2021.
2. Cosentyx Drug Evaluation. Express Scripts. January 2015

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

Policy History

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

05/07/2015 Medical Policy Committee review
05/20/2015 Medical Policy Implementation Committee approval. New policy.
03/03/2016 Medical Policy Committee review
03/16/2016 Medical Policy Implementation Committee approval. Added new indications psoriatic arthritis, ankylosing spondylitis and associated criteria.
03/02/2017 Medical Policy Committee review
03/15/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
12/07/2017 Medical Policy Committee review
12/20/2017 Medical Policy Implementation Committee approval. Removed the requirement for the use of Humira prior to Cosentyx. Updated TB test language.
12/06/2018 Medical Policy Committee review
12/19/2018 Medical Policy Implementation Committee approval. No change to coverage.
12/05/2019 Medical Policy Committee review
12/11/2019 Medical Policy Implementation Committee approval. No change to coverage.
11/05/2020 Medical Policy Committee review
11/11/2020 Medical Policy Implementation Committee approval. Added a new FDA approved indication for non-radiographic axial spondyloarthritis. Updated relevant background information.
08/05/2021 Medical Policy Committee review
08/11/2021 Medical Policy Implementation Committee approval. Updated the plaque psoriasis criteria to reflect the new FDA age expansion of 6 years of age and older (previously 18 years of and older). Also updated the relevant background information.

Next Scheduled Review Date: 08/2022

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. Reference to federal regulations.

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

secukinumab (Cosentyx™)

Policy # 00432

Original Effective Date: 05/20/2015

Current Effective Date: 09/13/2021

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.